A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
← catalyst calendarNCT07361497 · readout in 1,490 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →. With BioNTech SE.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
850estimated
Sites
258
Countries
Argentina, Australia, Austria +29
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-16 | actual | When the study began enrolling |
| Primary completion | 2030-09-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer (NSCLC)
Interventions
- Drug: Pumitamig — also filed as BMS-986545
- Drug: Durvalumab
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS) by blinded independent central review (BICR) (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)
measured Up to 3 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed